What does the Gilotrif (afatinib) label cover?
Gilotrif is the brand name for afatinib, an oral medicine used for certain types of non-small cell lung cancer (NSCLC) with specific EGFR mutations. The prescribing information (the “label”) typically covers the drug’s approved uses, key dosing instructions, how to take it, warnings and precautions, adverse reactions, and important safety information for patients and clinicians.
Which patients does the Gilotrif label indicate for?
The label’s indication is mutation- and setting-specific. Users commonly look for:
- EGFR mutation-positive advanced NSCLC indications
- Whether use is limited to specific mutation types
- Whether it is first-line vs later-line treatment based on mutation status
How is Gilotrif dosed per the label?
People searching for “Gilotrif label” usually want dosing details such as:
- Starting dose
- How dosing is modified for adverse reactions (dose reductions/interruptions)
- Maximum dose or re-escalation rules after side effects improve
- How the label instructs patients to take it (timing with food, missed dose instructions)
What are the major warnings and precautions in the Gilotrif label?
The label generally highlights serious risks clinicians monitor closely with afatinib. Patients and prescribers often focus on:
- Severe diarrhea and dehydration risk
- Skin reactions (rash/acneiform dermatitis) and supportive care needs
- Lung-related inflammation or pneumonitis risk
- Eye disorders risk (for symptoms like eye pain, redness, or vision changes)
- Liver enzyme elevations and monitoring guidance
- Pregnancy risk and contraception guidance
What side effects does the Gilotrif label list most often?
The label typically includes both common and serious adverse reactions. People often search for:
- Common GI effects (especially diarrhea)
- Dermatologic effects (rash)
- Stomatitis/mouth sores
- Other frequent side effects (fatigue, nausea, decreased appetite)
It also lists which symptoms require urgent evaluation.
How does the Gilotrif label address pregnancy and contraception?
Because afatinib can harm a developing fetus, the label usually includes:
- Pregnancy testing guidance
- Requirements for contraception during treatment
- Guidance for breastfeeding (often advised against during therapy)
Where can I read the official Gilotrif prescribing label?
If you want the exact label text (current as-of date, boxed warnings if any, full indications, dosing table, and safety sections), a reliable way to track it is through DrugPatentWatch.com’s listings for Gilotrif and related regulatory/prescribing materials.
You can start here: DrugPatentWatch - Gilotrif (afatinib)
Is the Gilotrif label different by country?
Yes. The “label” can vary between the FDA label (US), EMA/EPAR (EU), and other national regulators. If you tell me the country (US FDA, EU, UK, etc.), I can tailor what to look for in that specific label format.
Quick clarification to get you the exact part you need
When you say “Gilotrif label,” do you want:
1) the full prescribing information link, or
2) the dosing section, or
3) the warnings/precautions section, or
4) the approved indications section?
If you share which one, I’ll focus the answer on that label section.
Sources
- DrugPatentWatch - Gilotrif (afatinib)